RNA cleavage and inhibition of protein synthesis by bleomycin

被引:57
作者
Abraham, AT
Lin, JJ
Newton, DL
Rybak, S
Hecht, SM
机构
[1] Univ Virginia, Dept Chem, Charlottesville, VA 22901 USA
[2] Univ Virginia, Dept Biol, Charlottesville, VA 22901 USA
[3] NCI, Lab Biochem Physiol, Div Basic Sci, Frederick, MD 21702 USA
[4] NCI, Frederick Canc Res & Dev Ctr, Dev Therapeut Program, Div Canc Treatment & Diag, Frederick, MD 21702 USA
来源
CHEMISTRY & BIOLOGY | 2003年 / 10卷 / 01期
关键词
D O I
10.1016/S1074-5521(02)00306-X
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Bleomycin is a clinically used antitumor antibiotic long thought to function therapeutically at the level of DNA cleavage. Recently, it has become clear that bleomycin can also cleave selected members of all major classes of RNA. Using the computer program COMPARE to search the database established by the Anticancer Drug Screening Program of the National Cancer Institute, a possible mechanism-based correlation was found between onconase, an antitumor ribonuclease currently being evaluated in phase III clinical trials, and the chemotherapeutic agent bleomycin. Following these observations, experimentation revealed that bleomycin caused tRNA cleavage and DNA-independent protein synthesis inhibition in rabbit reticulocyte lysate and when microinjected into Xenopus oocytes. The correlation of protein synthesis inhibition to the previously reported site-specific RNA cleavage caused by bleomycin supports the thesis that RNA cleavage may constitute an important element of the mechanism of action of bleomycin.
引用
收藏
页码:45 / 52
页数:8
相关论文
共 51 条
[21]   SEQUENCE-SPECIFIC HYDROLYSIS OF YEAST TRNA(PHE) MEDIATED BY METAL-FREE BLEOMYCIN [J].
KECK, MV ;
HECHT, SM .
BIOCHEMISTRY, 1995, 34 (37) :12029-12037
[22]   DISCRIMINATION TECHNIQUES APPLIED TO THE NCI IN-VITRO ANTITUMOR DRUG SCREEN - PREDICTING BIOCHEMICAL-MECHANISM OF ACTION [J].
KOUTSOUKOS, AD ;
RUBINSTEIN, LV ;
FARAGGI, D ;
SIMON, RM ;
KALYANDRUG, S ;
WEINSTEIN, JN ;
KOHN, KW ;
PAULL, KD .
STATISTICS IN MEDICINE, 1994, 13 (5-7) :719-730
[23]   MAP-30 - A NEW INHIBITOR OF HIV-1 INFECTION AND REPLICATION [J].
LEEHUANG, S ;
HUANG, PL ;
NARA, PL ;
CHEN, HC ;
KUNG, HF ;
HUANG, P ;
HUANG, HI ;
HUANG, PL .
FEBS LETTERS, 1990, 272 (1-2) :12-18
[24]   CHARACTERIZATION OF THE MECHANISM OF CELLULAR AND CELL-FREE PROTEIN-SYNTHESIS INHIBITION BY AN ANTITUMOR RIBONUCLEASE [J].
LIN, JJ ;
NEWTON, DL ;
MIKULSKI, SM ;
KUNG, HF ;
YOULE, RJ ;
RYBAK, SM .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1994, 204 (01) :156-162
[25]  
MAGLIOZZO RS, 1989, MOL PHARMACOL, V35, P428
[26]  
Maniatis T., 1982, MOL CLONING A LAB MA
[28]   STRIKING INCREASE OF SURVIVAL OF MICE BEARING M109 MADISON CARCINOMA TREATED WITH A NOVEL PROTEIN FROM AMPHIBIAN EMBRYOS [J].
MIKULSKI, SM ;
ARDELT, W ;
SHOGEN, K ;
BERNSTEIN, EH ;
MENDUKE, H .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (02) :151-152
[29]  
MIKULSKI SM, 1993, INT J ONCOL, V3, P57
[30]   TAMOXIFEN AND TRIFLUOROPERAZINE (STELAZINE) POTENTIATE CYTOSTATIC CYTOTOXIC EFFECTS OF P-30 PROTEIN, A NOVEL PROTEIN POSSESSING ANTITUMOR-ACTIVITY [J].
MIKULSKI, SM ;
VIERA, A ;
ARDELT, W ;
MENDUKE, H ;
SHOGEN, K .
CELL AND TISSUE KINETICS, 1990, 23 (03) :237-246